Financial Data and Key Metrics Changes - Total operating expenses for Q1 2025 declined by 35% compared to Q1 2024, reflecting strong cost management across all spending categories [5][6][8] - Net cash used in operating activities was £4.3 million for Q1 2025, down from £8.3 million in Q1 2024, indicating improved cash flow management [6][10] - Revenue for the quarter was approximately $250,000, representing a 44% increase year-on-year, including the first revenue from human product sales [6][7][8] - Cash and cash equivalents at the end of Q1 2025 totaled approximately $2.6 million, down from $3.3 million at the end of 2024 [7] Business Line Data and Key Metrics Changes - The Nu. Q technology is being commercialized in the human diagnostic market, with significant licensing discussions ongoing with over 10 companies [11][12] - The Nu. Q cancer diagnostic pillar is progressing, with two major companies in active negotiations and a pivotal lung cancer screening study in Taiwan enrolling over 100 patients [14][15] - The Nu. Q NETs technology is also advancing, with a total addressable market for testing and monitoring intensive care patients estimated at $1 billion annually [17][18] Market Data and Key Metrics Changes - The combined market value of seven companies in licensing discussions exceeds $600 billion, highlighting the potential reach of the technology [12] - The total addressable market for cancer and sepsis diagnostics is estimated at $25 billion annually, presenting substantial revenue opportunities [12] Company Strategy and Development Direction - The company aims to achieve cash neutrality for the full year 2025, with a focus on reducing expenses and securing multiple licensing agreements in the human diagnostic space [5][10][36] - The strategy includes leveraging existing partnerships and expanding the global reach of the Nu. Q Vet cancer test while automating central labs to enhance revenue growth [24][25][36] - The company is focused on commercializing its technology quickly to make it accessible worldwide, with a mission to save lives and improve outcomes [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining low operating costs while focusing on commercialization efforts [41][44] - The company is optimistic about the progress made in licensing discussions and the potential for significant revenue generation from ongoing clinical studies [33][36] Other Important Information - The company recorded its first revenue from a regulated human product in the EU, marking a significant milestone [72] - Discussions are ongoing with several national lung screening programs, indicating strong interest in the company's diagnostic solutions [34] Q&A Session Summary Question: Is the current low level of operating expenses sustainable for the rest of 2025? - Management confirmed that maintaining low costs is a priority and that they have made significant progress in controlling expenses across all categories [41][42][44] Question: Update on the progress of the feline cancer test? - Management reported that pre-analytics work for the feline cancer test has been completed, and clinical data collection is underway [45][48] Question: What is the operational engagement with partners like Texas A&M and IDEXX? - Management indicated that while they know the volume of purchases, detailed sales flow information is typically not shared due to commercial sensitivity [54][55] Question: Will marketing expenses remain flat for the rest of the year? - Management stated that while they plan to spend less overall, there may be fluctuations in spending due to conference attendance and other marketing activities [58][60] Question: When will revenues from the human study contract in Nu. Q Discover be recognized? - Management noted that the clinical study will run over two years, with revenues expected to be spread out over that period [64][65]

Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be ...

Financial Performance - Total revenues for Q1 2025 were $246,385, a 43.6% increase from $171,535 in Q1 2024[24] - Service revenues increased significantly to $115,476 in Q1 2025 from $2,938 in Q1 2024[24] - Operating loss for Q1 2025 was $5,521,720, improved from a loss of $8,384,504 in Q1 2024[24] - Net loss attributable to VolitionRx stockholders for Q1 2025 was $5,423,759, compared to $8,367,388 in Q1 2024[24] - The net loss for the three months ended March 31, 2025, was $5,476,627, a 35% improvement compared to a net loss of $8,472,005 in the same period in 2024[162] - The company's net loss was $5.5 million, a decrease of approximately $3.0 million compared to a net loss of $8.5 million for the three months ended March 31, 2024[172] Cash and Liquidity - Cash and cash equivalents decreased to $2,600,342 as of March 31, 2025, down from $3,264,429 at the end of 2024[21] - The company experienced a net cash used in operating activities of $4,298,018 in Q1 2025, an improvement from $8,342,384 in Q1 2024[30] - As of March 31, 2025, the company had cash and cash equivalents of $2.6 million and an accumulated deficit of $235.0 million[48] - The company has determined there is substantial doubt about its ability to continue as a going concern without further financing[173] - The company plans to seek additional capital through the sale of debt or equity securities, which may dilute existing stockholders' ownership[175] Expenses and Cost Management - Research and development expenses for Q1 2025 were $2,607,444, down from $4,629,527 in Q1 2024[24] - Total operating expenses reduced to $5.8 million for the three months ended March 31, 2025, down from $8.6 million in the same period in 2024, reflecting a 33% decrease[162][164] - General and administrative expenses decreased to $2.2 million from $2.3 million, a decline of about 2.2% for the three months ended March 31, 2025, compared to the same period in 2024[167] - Sales and marketing expenses decreased to $0.9 million from $1.7 million, a decrease of approximately 46.1% for the three months ended March 31, 2025, compared to the same period in 2024[169] - The company continues to exercise tight cost controls to conserve cash, including directors and employees exchanging part of their fees for RSUs[50] Stock and Financing Activities - The company raised $2,384,654 from issuances of common stock in Q1 2025, compared to $15,733 in Q1 2024[30] - The company raised net proceeds of $2.3 million from the issuance of 4,102,723 shares at an offering price of $0.55 per share in March 2025[67] - In August 2024, the company raised net proceeds of $6.4 million from the sale of 9,170,000 shares and warrants, with a combined offering price of $0.55 per share[68] - The Company entered into a Capital On DemandTM Sales Agreement to sell shares of common stock with an aggregate offering price of up to $7.5 million[128] - The Company entered into a Securities Purchase Agreement with Lind Global Asset Management for $6,250,000 in funding, issuing a Senior Secured Convertible Promissory Note of $7,500,000 and a warrant for 13,020,834 shares at $0.672 per share[150] Assets and Liabilities - Total current liabilities increased to $8,273,099 as of March 31, 2025, compared to $7,790,747 at the end of 2024[21] - The company reported a total stockholders' deficit of $29,026,675 as of March 31, 2025, compared to $26,107,736 at the end of 2024[23] - The total balance for long-term debt payable was $6,394,857, with $1,065,503 due in 2025 and $3,220,798 due in 2028[105] - The total property and equipment as of March 31, 2025, was $9.76 million, with a net value of $4.35 million after accumulated depreciation[55] Research and Development - The company launched the Nu.Q® Vet Cancer Test in the UK and Ireland in November 2023 and in Japan in July 2024, expanding its market presence[148][149] - The company received a $10 million upfront payment from Heska for exclusive rights to sell the Nu.Q® Vet Cancer Test for companion animals, with potential additional milestone payments[144] - The number of full-time equivalent personnel in the research and development division decreased by 14 to 52 compared to the prior year period[165] Internal Controls and Compliance - The company identified a material weakness in its internal controls over financial reporting and is actively working on remediation plans[187] - The company has no known legal proceedings that it believes will have a material adverse effect on its financial position[115]

Financial Performance - VolitionRx Limited reported financial results for Q1 2025, with a total revenue of $2.5 million, representing a 25% increase compared to Q1 2024[6] Business Strategy - The company confirmed a conference call scheduled for May 16, 2025, to discuss these results and business updates[6] - VolitionRx is focusing on expanding its product offerings and enhancing its technology for better market penetration[6]

HENDERSON, Nev., April 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that President and Group Chief Executive Officer, Cameron Reynolds, has issued a Shareholder Letter providing a business update.A Message from our Chief Executive Officer2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the human diagnostics market. I am delighted to report we are in confidential di ...

Financial Data and Key Metrics Changes - In 2024, the company recorded $1.2 million in revenue, a growth of 59% over 2023 [28] - Revenue from the NUQ VET cancer test was $0.8 million, growing by 75% compared to the prior year [28] - Operating expenses were reduced by 23% year-on-year, with second-half operating expenses down 31% [30][34] - Net cash used in operating activities was $25.9 million in 2024, compared to $18.1 million in 2023 [31] Business Line Data and Key Metrics Changes - Approximately 120,000 NUQ VET cancer tests were sold in 2024, more than double the prior year [28] - Revenue from the NUQ Discover pillar was approximately $400,000, with year-on-year growth of 40% [29] - The company recorded its first revenue from NUQ NETS, marking a significant milestone [29] Market Data and Key Metrics Changes - The NUQ VET cancer test is now available in over 20 countries, expanding access significantly [18] - The point-of-care market is noted to be less than 20% of the total market, indicating growth potential [22] Company Strategy and Development Direction - The company aims to sign multiple licensing deals in 2025, focusing on human applications [11][68] - There is a strong interest in out-licensing and supply agreements for both NUQ NETS and the oncology portfolio [12][69] - The strategy includes raising non-dilutive funds, ramping revenues, reducing expenses, and signing commercial deals with large industry players [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash neutrality on a full-year basis by 2025 [27] - The company is at a pivotal juncture, ready to revolutionize diagnostics for both animals and humans [12] - Management highlighted the importance of automation in centralized labs to accelerate growth [22] Other Important Information - The company received approximately $1.8 million in non-dilutive funding from Belgian institutions during 2024 [33] - Significant progress was made in clinical studies, with multiple large independent studies completed [10][36] Q&A Session Summary Question: Update on the feline cancer testing program - The feline cancer testing program is on track for completion later this year, with a milestone payment of $5 million expected upon completion [80] Question: Discussion on the Leon study and its implementation - The Leon study is expected to lead to prospective studies and potential implementation in screening regimens [85][90] Question: Insights on quarterly sales trends and outlook for 2025 - Sales were volatile due to large customers ordering in batches, but overall growth was solid with 120,000 tests sold [100][102] Question: Approach to managing financing risks - The company plans to maintain tight control over expenses and cash flows while focusing on licensing agreements [112] Question: Activity in data sharing and licensing agreements - The company has established data rooms for oncology and NETS, which have energized discussions with major companies [118][120]

VolitionRX Limited (VNRX) Q4 2024 Earnings Conference Call March 31, 2025 04:30 PM ET Company Participants Operator - Conference Call OperatorLouise Batchelor - Group Chief Marketing and Communications OfficerModerator - Conference Call ModeratorCameron Reynolds - Group Chief Executive OfficerTerry Cuse - Group Chief Financial OfficerTerry Cuse - Group Chief Financial OfficerDr. Andrew Retter - Chief Medical Officer Conference Call Participants Stephen Ralston - Analyst at ZaxBruce Jackson - Analyst, Benchm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) 1489 West Warm Springs Road, Suite 110 Delaware (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification Number) Check the appropriate box below if the Form 8-K filing is intended ...

Cameron Reynolds, President and Group Chief Executive Officer, said: "Our focus in 2024 was on generating sufficient clinical data to convince the biggest players in the diagnostic, screening, and liquid biopsy world that our Nu.Q® platform will play a significant role in both the oncology and sepsis markets. I believe this was achieved beyond our expectations: a range of independent studies demonstrating the value of our platform have been completed. We built impressive data rooms in 2024, and 2025 will se ...